GSK will present data from the P-III (ZOSTER-049) study following individuals for ~11yrs. post initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV) at ESCMID Global 2024
The P-III (ZOSTER-049) study assessed the safety, efficacy & immunogenicity of Shingrix in individuals (n=7000, ≥50yrs.) for an additional 6yrs. following the conclusion of ZOE-50 & ZOE-70 trials, making it a total of ~11yrs. of follow-up
The study demonstrated a vaccination efficacy (VE) of 79.7% from 6 to 11yrs. and 82.0% at 11yrs. in adults ≥50yrs. of age. Vaccination efficacy was 73.1% in adults ≥70yrs. of age from 6 to 11yrs. showing greater VE rates among all groups
Ref: GSK | Image: GSK
Related News:- GSK Reports P-IV Trial (ZOSTER-076) Results of Shingrix (Recombinant Zoster Vaccine) for the Prevention of Shingles in Adults aged ≥50 Years in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
